Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC plus Nivolumab for Advanced or Recurrent Gastric Cancer
KCT0005542Phase 2Completed
- Sponsor
- Yonsei University Health System
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immuncell-lc and nivolumab in gastric cancer (GC), sponsored by Yonsei University Health System. Primary endpoints: Efficacy (primary) and Safety and tolerability. Started Jul 2021; status: completed.
02
Drugs
immuncell-lcnivolumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0005542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005542.